Industry news

A new normal in China for pharmaceutical industry as reforms accumulate?

EJ Lane / FeircePharmaAsia

Second-quarter earnings from nearly all multinationals showed a drop in business in China from double-digit paces in recent years, blamed on tough tender and reimbursement policies and domestic competition as well as an economic slowdown.

Study: Device industry suffers from first-mover disadvantage due to FDA regs

Varun Saxena / FierceMedicalDevices

The first high-risk medical device in a given category--such as a coronary stent or transaortic valve replacement--takes 34% longer to be approved than a follow-on version from a competitor, finds a Harvard Business School study.

Drug Delivery Systems for Biopharmaceuticals

Adeline Siew, PhD / BoiPharm International

Industry experts discuss key considerations in the development of a drug-delivery device for a biologic drug.

11 August 2015

Tobira Therapeutics Reports Second Quarter 2015 Financial Results

Tobira Therapeutics, Inc. (TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for nonalcoholic steatohepatitis (NASH) and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the second quarter of 2015.

11 August 2015

Epic Sciences Publication Validates Unbiased Detection of Circulating Tumor Cells (CTCs) from a Liquid Biopsy

Epic Sciences announced today the publication of its research in the Journal of Circulating Biomarkers validating the company's no cell left behind™ platform. The data published demonstrate reproducible and linear assay performance in CTC enumeration as well as additional utility in downstream molecular characterization of single CTCs, including protein biomarker analysis and single cell genomics. 

Big pharma continues to invest in immuno-oncology innovation

Peter Winter / BioWorld

Big pharmas are continuing to exhibit a healthy appetite for deal making, particularly for early stage therapeutic assets. Last week, for example, Merck & Co. Inc. scooped up a small Israeli biotech, Ccam Biotherapeutics Ltd., to add its immuno-oncology (I-O) pipeline. The space is hot and like many big pharmas, Merck is "scouring the world, looking for immunomodulatory agents," according to Eric Rubin, vice president and therapeutic area head of oncology early stage development at Merck Research Laboratories.

Asia in the Spotlight: Employers Build Wellness Culture with Aid of Wearable Technology

Cornelia Zou / BioWorld

More device and data service companies are tapping into the $6 billion corporate wellness tracking business and Asian companies are finding that they have the tools to track the health of their employees with simple wearable devices and tailor-made features.

DNAnexus teams up with FDA for Precision Medicine cloud-based genomics platform

Emily Wasserman / FierceDiagnostics

DNAnexus has not wasted any time expanding the reach for its cloud-based data platform, roping in funds from the likes of Google ($GOOG) and striking major deals to further its data hub ambitions. In its latest win, the company inked a deal with the FDA to create the agency's new cloud-based genomics platform under President Obama's Precision Medicine initiativ

Biotech's top boomtowns: Rising rents, growing salaries and larger ranks

John Carroll / FierceBiotech

The higher rents rise in the Boston/Cambridge biotech hub, the hotter its rep as the go-to life sciences cluster in the U.S. A new survey from the property analysts at JLL, or Jones Lang LaSalle, ranked Beantown as the top biotech cluster in America, followed by Raleigh-Durham, San Francisco, San Diego and New York City

Think tank: Time to look beyond the gold standard in drug R&D

Mark McCarty and Mari Serebrov / BioWorld

As technology pulls medical innovation into the 21st century, the burnish may be wearing off randomized, controlled trials (RCTs), the FDA's longtime gold standard for developing new therapies.